BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets open in 9 hrs 15 mins

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
268.53-5.58 (-2.04%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close274.11
Bid268.27 x 100
Ask268.51 x 300
Day's Range268.20 - 273.91
52 Week Range223.02 - 333.65
Avg. Volume1,669,595
Market Cap57.99B
PE Ratio (TTM)15.86
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia7 hours ago

    Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis

    Roche Holdings AG RHHBY announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis. Roche’s share price ...

  • Roche Multiple Sclerosis Drug OK Bittersweet For Beleaguered Biogen
    Investor's Business Daily8 hours ago

    Roche Multiple Sclerosis Drug OK Bittersweet For Beleaguered Biogen

    The FDA's approval of a multiple sclerosis drug from Roche is likely to be bittersweet for Biogen, analysts said Wednesday.

  • Reuters15 hours ago

    U.S. approves Roche drug that targets severe form of MS

    Roche's multiple sclerosis (MS) drug Ocrevus won U.S. approval, putting the potential blockbuster back on track after a brief delay and giving a lift to patients with a form of the disease that until now had no approved treatment. The drug, also known as ocrelizumab and administered via infusion, becomes the first U.S. Food and Drug Administration-approved medicine for the primary progressive form of the neurological disease (PPMS). Ocrevus, to have a list price of $65,000 annually, undercutting rival Merck's Rebif by a quarter, is also approved to treat the most common form of MS, known as relapsing-remitting multiple sclerosis (RRMS).